-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EQZzIofONwzhRf2AmTsEbL3QKiZ72ZVhafdlCPagbt+h/ASkOQv0qR1vDS6ndzbG epXt4Q2nkZPqnq7yacQJtA== 0001169232-03-003122.txt : 20030422 0001169232-03-003122.hdr.sgml : 20030422 20030422152106 ACCESSION NUMBER: 0001169232-03-003122 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030228 FILED AS OF DATE: 20030422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MILLENIA HOPE INC CENTRAL INDEX KEY: 0001060827 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980213828 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-29385 FILM NUMBER: 03658336 BUSINESS ADDRESS: STREET 1: 4055 ST. CATHERINE ST STREET 2: SUITE 142 H3Z 3J8 CITY: MONTREAL QUEBEC STATE: A6 ZIP: 62704 BUSINESS PHONE: 5148465757 MAIL ADDRESS: STREET 1: 4055 ST. CATHERINE ST STREET 2: SUITE 142 H3Z 3J8 CITY: MONTREAL QUEBEC STATE: A6 10-Q/A 1 d55309_10q-a.txt AMENDMENT TO FORM 10-Q Document is copied. MILLENIA HOPE INC. (Exact name of Small Business Issuer as Specified in its Charter) DELAWARE 98-0213828 (state or other Jurisdiction of (I.R.S Employer Incorporation or Organization) Identification No.) 4055 Ste Catherine st. suite 142, Montreal, Quebec H3Z 3J8 (Address of Principal Executive Offices) (514) 846-5757 Issuer's Telephone Number Including Area Code) State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: At February 28, 2003 Issuer had 39,570,945 outstanding shares of Common Stock. INDEX PART I: FINANCIAL INFORMATION Item 1. Financial Statements Consolidated Balance Sheet (Unaudited) at February 28, 2003. Consolidated Statement of operations (Unaudited) for the three months ended February 28, 2003 and February 28, 2002 and from inception (December 24, 1997) to February 28, 2003. Consolidated Statements of cash flows (Unaudited) for the three months ended February 28, 2003 and February 28, 2002 and from inception (December 24, 1997) to February 28, 2003. Notes to the Financial Statements (Unaudited) Item 2. Plan of Operations PART II. Other Information Item 2. Sale of Unregistered Securities Item 6. Exhibits and Reports on Form SIGNATURES MILLENIA HOPE INC. (A COMPANY IN THE DEVELOPMENT STAGE) CONSOLIDATED BALANCE SHEET AT FEBRUARY 28, 2003 (UNAUDITED) Assets Current Assets Cash and cash equivalents $ 0 Accounts Receivable 76,147 Note Receivable - Related Party 99,316 Other current assets 120,000 ----------- Total current assets 295,463 Property and equipment, net 36,479 Other Asset 1 ----------- Total assets 331,943 =========== Liabilities and Shareholder's Equity Current Liabilities Bank Indebtedness 4,586 Accounts payable and accrued liabilities 257,901 Notes payable (principally related parties) 103,442 Other current liabilities 0 ----------- Total current liabilities 365,929 Minority Interest 104,499 Shareholder's Equity Common Stock, $.0001 par value; authorized 70,000,000 shares; issued and outstanding 39,570,945 3,957 Warrants 1,393,247 Paid in Capital 6,990,630 Cost of Treasury Shares 100 Deficit accumulated during the development stage (8,526,419) ----------- Total Shareholder's Equity (138,485) Total liabilities and shareholder's equity $ 331,943 =========== Read the accompanying significant notes to financial statements, which are an integral part of this financial statement. MILLENIA HOPE INC. (A COMPANY IN THE DEVELOPMENT STAGE) CONSOLIDATED STATEMENT OF OPERATIONS FOR THE 3 MONTHS ENDED FEBRUARY 28, 2003 AND FEBRUARY 28, 2002 AND THE PERIOD FROM INCEPTION (DECEMBER 24, 1997) TO FEBRUARY 28, 2003. (UNAUDITED)
INCEPTION (Dec. 24, 1997) February 28, 2003 February 28, 2002 Feb.28, 2003 ----------------- ----------------- ------------ Revenue: $ 47,630 $ 120,158 $ 1,118,848 Cost of Revenues 24,352 40,154 603,563 ------------ ------------ ------------ 23,278 80,004 515,285 Operating expenses: Marketing 102,750 -- 817,226 Patent Rights -- -- 27,770 Other Development Costs -- -- 921,177 Travel -- -- 234,859 Rent 14,650 23,600 366,905 Selling, General and administrative expenses 13,162 39,176 1,455,972 ------------ ------------ ------------ Total operating expenses 130,562 62,776 6,162,492 Income (Loss) before other income (expense) (107,284) 17,228 (5,647,207) ------------ ------------ ------------ Other income (expense): Writedown-leaseholds -- -- (2,663) Writedown-other assets -- -- (2,799,999) Gain (Loss) on disposition of shares 25,000 -- 15,453 Interest expense related party (1,711) (3,403) (180,923) Interest income related party 1,708 2,778 14,139 ------------ ------------ ------------ Total other income (expense) 24,997 (625) (2,953,993) ------------ ------------ ------------ Net Income (Loss) before Minority Interest (82,287) 16,603 (8,601,000) Minority Interest in net income (loss) of subsidiary (2,582) 15,272 (74,581) Net Income (loss) (79,705) 1,331 (8,526,419) ============ ============ ============ Basic weighted average common shares outstanding 39,570,945 35,567,752 21,362,618 ============ ============ ============ Basic Loss per common share $ (0.0025) $ 0.0000 $ (0.4000) ============ ============ ============
Read the accompanying notes to financial statements, which is an integral part of this financial statement. MILLENIA HOPE INC. (A COMPANY IN THE DEVELOPMENT STAGE) CONSOLIDTAED STATEMENT OF CASH FLOWS FOR THE THREE MONTHS ENDED FEBRUARY 28, 2003 AND FEBRUARY 28, 2002 AND THE PERIOD FROM THE INCEPTION (DECEMBER 24, 1997) TO FEBRUARY 28, 2003 (UNAUDITED)
Three Months Inception Ended February 28, (December 24, 1997) ----------------------- through 2003 2002 February 28, 2003 ------- ------- ------------------- CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss) (79,705) 1,331 (8,526,419) Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization 3,400 6,715 112,795 Issuance of stock for services 33,450 -- 1,818,829 Issuance of note for other development costs -- -- 817,226 (subsequently converted to warrants) Interest expense settled with issuance of note (subsequently converted to warrants) -- -- 27,770 Interest expense - related party 1,711 3,403 31,285 Interest income - related party (1,708) (2,778) (14,139) Write down note receivable -- -- 70,000 Settlement of Subscription receivable for services -- -- 256,250 Sale of Investment in Subsidiary for services -- -- 10,800 Write down leaseables -- -- 2,663 Write down other assets -- -- 2,799,999 Loss on disposition of shares of subsidiary -- -- 9,547 Changes in Operating assets and liabilities: Receivables and other Assets (24,350) (21,458) (161,324) Payables and Accrued Liabilities (31,424) (16,924) 257,901 ------- ------- ---------- Net cash provided by/(used in) operating activities (35,778) (29,711) (2,486,817) CASH FLOWS FROM INVESTING ACTIVITIES: Bank Indebtedness 298 (1,186) 4,586 Purchase of Property and equipment -- -- (128,715) Issuance of stock for subsidiaries cash balance -- -- 40,628 Repayment of subsidiary related party note receivable -- -- 34,233 Collection of subsidiary share subscription receivable 23,750 -- 107,081 Minority interest portion of net income/(loss) of subsidiary (2,582) 15,272 (74,581) Deposits on future acquisitions -- -- (1,000,000) ------- ------- ---------- Net cash provided by/(used in) investing activities 21,466 14,086 (1,016,776) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from: Notes payable, principally related parties 3,000 -- 1,371,245 Issuance of stock 11,312 15,625 967,348 Contribution to Paid in Capital -- -- 1,165,000 ------- ------- ---------- Net cash provided by/(used in) financing activities 14,312 15,625 3,503,593 ------- ------- ---------- Net increase (decrease) in cash and cash equivalents -- -- -- Cash and cash equivalents, beginning of period -- -- -- ------- ------- ---------- Cash and cash equivalents, end of period -- -- -- ======= ======= ==========
Supplemental Schedule of noncash investing and financing activities: On February 28, 2000, the company issued 4,644,156 warrants to settle the following related party notes: Notes payable (principally related parties) (net of discount) 1,172,648 Long-term debt, less current portion (net of discount) 104,031 Current portion of long term debt (net of discount) 88,800 Current year interest expense 27,770 --------- 1,393,249 On May 29, 2000, the company issued 5,000,000 shares of common stock in exchange for 35,700,000 shares of Sword Comp-Soft Corp, a Delaware corporation which provides on-line interactive health services through the Internet. The transaction was recorded using the "purchase method" as the registrant acquired 76,54% of Sword Comp-Soft Inc's outstanding shares at May 29, 2000. The following assets were acquired through this transaction: Notes Receivable - 3rd Party 33,600 Notes Receivable - Related Party 34,233 Property and Equipment, net 23,221 The following liabilities were assumed through this transaction: Accounts payable and accrued liabilities 4,500 On April 30, 2000, the company's subsidiary issued 600,000 shares for Equipment valued at $15,000. On October 12, 2001 the company issued 7,000,000 common shares to acquire other assets valued at $2,294,541. On October 12, 2001 the company divested itself of 1,000,000 common shares that it owned of its subsidiary for other assets valued at $5,459. MILLENIA HOPE INC. (A COMPANY IN THE DEVELOPMENT STAGE) NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) FEBRUARY 28, 2003 NOTE 1 - BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of Millenia Hope Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-QSB and Article 10 of Regulation S-X. The financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair presentation of the results for the periods shown. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and footnotes thereto included in Millenia Hope Inc.'s on Form 10KSB as filed with the Securities and Exchange Commission. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and that effect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The company currently recognizes revenue in the form of direct sales to the retail market and licensing fees, which are recorded over the life of the licensing agreement using the straight-line method. Currently the company has one agreement with a term of 5 years commencing on January , 1999. The company also recognizes revenue from its subsidiary, providing technology related services, such internet site hosting and software consulting. Revenue is recognized when the service is performed. In December 1999, the Securities and Exchange Commission ("SEC") issued Staff Accounting Bulletin No. 101 ("SAB 101"), "Revenue Recognition," which provides guidance on the recognition, presentation and disclosure of revenue in financial statements filed with the SEC. SAB 101 outlines the basic criteria that must be met to recognize revenue and provide guidance for disclosures related to revenue recognition policies. Management believes that Millenia Hope Inc.'s revenue recognition practices are in conformity with the guidelines of SAB 101. NOTE 3 - NET LOSS PER SHARE Basic earnings (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Options and warrants are not considered since considering such items would have an antidilutive effect. NOTE 4 - GOING CONCERN The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The company reported a net loss of $79,705 for the three months ended Feb 28, 2003 as well as reporting net losses of $8,526,419 from inception (December 24, 1997) to February 28, 2003. As reported on the statement of cash flows, the Company had negative cash flows from operating activities of $ 35,778 for the three months ended February 28, 2003 and has reported deficient cash flows from operating activities of $ 2,486,817 from inception (December 24, 1997). To date, these losses and cash flow deficiencies have been financed principally through the sale of common stock $ 967,348 and short term debt $ 1,371,245 which is principally related party debt. Additional capital and/or borrowings will be necessary in order for the Company to continue in existence until attaining and sustaining profitable operations. Management has continued to develop a strategic plan to develop a management team, maintain reporting compliance and establish long term relationships with other major organizations to develop and distribute the product Malarex. Management anticipates generating revenue through the sales of Malarex(TM) during the next fiscal year. The major shareholder's of the organization have committed to fund the operations of the organization during the next fiscal year until the organization can generate sufficient cash flow from operations to meet current operating expenses and overhead. NOTE 5 - ACQUISITION OF SWORD COMP-SOFT On May 29, 2000, the company issued 5,000,000 shares of common stock in exchange for 35,700,000 shares of Sword Comp-Soft, Corp., a Delaware corporation which provides on-line interactive health services through the internet. The transaction was recorded using the "purchase method" as the registrant acquired 76.45% of Sword Comp-Soft, Corp.'s outstanding shares at May 29, 2000. On March 5, 2003, the Company signed an agreement with its subsidiary company to sell to Sword all of the common shares that it held at that date, 30.7 million shares. The Company will receive from its subsidiary $700,000, due no later than March 5, 2004. A portion of this amount will be allocated to reduce the note payable to Sword. In addition, Sword will transfer all rights and ownership of the Application Service Provider in the E-Health Sector business to Millenia. NOTE 6 - STOCKHOLDER'S EQUITY Between December 5th and February 28th, the Company sold 426,250 shares of common stock pursuant to Regulation S, 200,000 shares were in settlement of marketing expenses. NOTE 7 - PATENT RIGHTS On May 31, 2001, Millenia Hope and Liquid Asset Corp signed a finalized purchase agreement that gives Millenia Hope the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 years period. The purchase price for these rights to September 1, 2005, is $ 500,000 cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of its subsidiary, Sword Comp-Soft Corp, that were owned by Millenia. NOTE 8 - OTHER ASSETS On October 9, 2001, Millenia Hope acquired a 68% interest in assets, comprised of land, plant and equipment located in Brazil to be used in the production of MalarexTM. The purchase price was $500,00 cash, 7 million Millenia Hope shares and 1 million non-registered common shares of its subsidiary, Sword Comp-Soft Corp, that were owned by Millenia. These assets were to have been transferred to a newly formed corporation to be owned 68% by the company by October 7, 2002. As this never occurred and due to the inability to legally register ownership in the facility, the company has written down assets to $1. Plan of Operation. The following discussion should be read in conjunction with the financial statements and related notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product. The business objectives of Millenia are twofold. First and foremost is to establish MALAREX as an accepted control agent for the treatment and prevention of malaria throughout the world. Not only do we believe that MALAREX is an effective anti-malarial drug, it will also be made available at prices that are adapted to the realities of the third world market. The availability and pricing of MALAREX, we believe, will ensure its acceptability and use in the fight against malaria. To this end the company is involved with ongoing clinical trials of MALAREX. As of February 28, 2003, Millenia Hope had received 8 sales authorizations from West African nations, Congo (Brazzaville) and Guinea (Conakry), Togo, Burundi, Central African Republic, Benin, Gabon and Chad. We are awaiting sales authorizations from several other West African nations. Based on managements best estimates, Millenia hopes to sell up to 1 million treatments of Malarex or $7 million worth, by the end of fiscal 2003. Millenia has adopted an extremely conservative sales forecast. In the face of anti-malarial drug resistance, the need for more effective treatments will continue to intensify. Once a network of local manufacturers and distributors capable of producing and supplying MALAREX are in place, the demand for MALAREX should increase commensurately. It is estimated the demand for MALAREX will increase as it becomes one of the accepted choices in the fight against malaria. Millenia has chosen to remain conservative and has established a goal of capturing 2% ($200 million) of the marketplace in five years. According to the company's internal estimates, based upon it's knowledge of the industry, attaining this sales level will ensure the viability and profitability of the Company for its shareholders. No assurance can be given that the Company will meet its sales goals. Secondly, Millenia is committed to ongoing research and development to expand the efficacy of MALAREX and its derivatives in fighting infectious diseases. As the company has not yet made any significant sales of its product, it is difficult for management to evaluate the growth curve of Product sales. However, given the market size and the need for viable and effective drugs, the Company believes that it will not have a problem generating sales thereby creating positive cash flow once further authorizations have been obtained. On May 29, 2000, the company acquired thirty five million seven hundred thousand (35,700,000) shares of SWORD COMP-SOFT CORP., this being 76.5% of SWORD's issued capital, at a cost of five million (5,000,000) common shares, and five million warrants (5,000,000), entitling the registered holder thereof to purchase at any time from that date for a period of three (3) years, one share of common stock at a price of two dollars ($2). SWORD COMP-SOFT CORP. was an (ASP) Application Service Provider incorporated in November 1998 specializing in the E-Healthcare sector. Application services, a rapidly growing segment of the Internet economy, are those that focus on a single topic or issue in a conversational manner. Essentially, the subscribers use application programs to create, store and transact medical data on the application server, for example, the interactive on-line health service will record similar data to that usually given to a primary health care worker, such as a doctor or a nurse,, and create an overall profile of individual health needs. Each application will relate to a specific disease, drug, or part of the human anatomy on a pay per use basis ( although this fee may be sponsored). On March 5, 2003, Millenia divested its entire holding in Sword Comp-Soft, this being 30.7 million common shares. The aforementioned shares were tendered back to Sword Comp-Soft. In exchange for said 30.7 million shares, Sword Comp-Soft paid Millenia Hope $700,000 U.S., due within 12 months from the date of its signing of the agreement and gave Millenia its Medico Center site, Medico Research, any other related Medico ASP work and all the attended backup documentation, computer line code etc., all is per the agreement signed on March 5, 2003. The acquisition of Sword`s medical ASP's and Medico Records accessible on the Internet, where 45% of all inquiries are health related, is highly beneficial, as Millenia's scientific advisory committee, comprised of M.D.s and P.H.D.s with a wide range of expertise, will lend valuable assistance as we strive to bring to the market medical ASPs. Further, their breadth of knowledge and varied specializations should help to generate ideas and data to aid in the production of other medical ASP's. On October 10, 2001 Millenia Hope and Cibecol Industrial Farmaceutica Ltda. Signed a purchase agreement via which Millenia will acquire 68% of the assets of Cibecol for $500,000 in cash, 7 million shares of Millenia Hope common shares and 1 million common shares of Sword Comp-Soft., a subsidiary of Millenia Hope, that are owned by Millenia. Cibecol, incorporated and headquartered in Brazil, operates a 20,000 square foot manufacturing facility and also owns 82 hectares of arable land, located, Porto Allegre, Brazil. Millenia will use the Brazilian facility for the production of Malarex. Cibecol, which has been in business for over 20 years, operates one of the largest phyto-pharmaceutical plants in southern Brazil. In addition to producing voacamine, the active agent in Malarex, Cibecol would continue to produce its own group of 61 natural medicines that are currently being Marketed in Brazil. This acquisition would be a key step forward toward Millenia's goal of becoming a vertically integrated producer and distributor of Malarex. Furthermore, Millenia, under the leadership of Dr. David Mulder, Millenia's Vice Chairman, and Dr. Rene Morel, a member of our scientific committee, expect to introduce a new concept which we call 02-IV, oxygenation of intravenous solutions. Intravenous solution recipients will now be able to derive a positive boost from the extra dose of oxygen delivered directly to their blood stream. The North American intravenous solution market, per estimates of Frost & Sullivan, is approximately $1.3 billion and the rest of the international market is about an additional $1.5 billion. On May 31, 2001, Millenia Hope and Liquid Asset Corp. signed a purchase agreement, the terms of which give Millenia the exclusive worldwide rights to oxygenate intravenous solutions until September 1, 2005 with an option to purchase these same rights for a further 5 year period. The purchase price for these rights to September 1, 2005 is $500,000 in cash, 6 million Millenia Hope common shares and 2 million non-registered common shares of Sword Comp-Soft Corp. that are owned by Millenia. Millenia has come to an agreement to utilize the services of Ropack, an FDA approved, HACCP and cGMP Compliant and ISO 9002 certified corporation, to perform quality control and all encapsulating of MALAREX(TM), confirming to U.S. and Canadian manufacturing standards. Assure the highest possible level of quality via product analysis and homogeneity testing for MALAREX(TM). This manufacturing facility, fully adhering to the highest quality standards of good manufacturing procedures, gives credence and assurance of the purity and safety of our final product. Ropack is accredited by both the U.S. and Canadian armies. Liquidity and cash flow needs of the company From December 1st, 2002 to February 28, 2003 the company and its subsidiary incurred operating and interest expenses in the amount of $129,914 while recording net cash revenues of $47,630. from March 1st, 2003 to November 30th, 2003, the fiscal year end, the company anticipates that its net cash flow needs, will be $650,000 primarily to cover day today operating expenses. These funds will be covered by revenue received and any shortfalls will be met by the officers and certain shareholders as previously outlined. Part II other information Item 2: Sales of Unregistered securities Date of Title of Number Consideration Exemption from Sale Security Sold Received Registration claimed 12/05/2002 common shares 200,000 $14,000 Regulation S in settlement of marketing expenses 2/28/2003 common shares 226,250 $11,312 Regulation S (b) Reports on Form 8-K None SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Millenia Hope Inc. (Registrant) Dated April 15, 2003 By: /s/ Leonard Stella Chief Operating officer /s/ George Tsoukas --------------------------------- George Tsoukas Chairman of Board (Principal Executive Officer) Certification of Principal Executive Officer and Principal Financial Officer 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 The undersigned, the Principal Executive Officer (Chairman of the Board) and the Principal Financial Officer (Chief Operating Officer) of Millenia Hope Inc. (the "Company"), each hereby certifies that to his knowledge on the date hereof: (c) The Quarterly Report on Form 10-Q SB of the Company for the quarter ended February 28, 2003, filed on the date hereof with the Securities and Exchange Commission (the "Report") fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and (d) Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: April 22, 2003 /s/ George Tsoukas ---------------------------------- George Tsoukas Chairman of Board (Principal Executive Officer) Date: April 22, 2003 /s/ Leonard Stella ---------------------------------- Leonard Stella Chief Operating Officer (Principal Financial Officer) This certification accompanies the Report pursuant to the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. FORM OF OFFICER'S CERTIFICATE PURSUANT TO SECTION 302 The undersigned Principal Executive Officer (Chairman of Board) of Millenia Hope Inc., hereby certifies that: 1. he has reviewed the report; 2. based on his knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report; 3. based on his knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in the report; 4. he and the other certifying officers: a. are responsible for establishing and maintaining "disclosure controls and procedures" (a newly-defined term reflecting the concept of controls and procedures related to disclosure embodied in Section 302(a)(4) of the Act) for the issuer; b. have designed such disclosure controls and procedures to ensure that material information is made known to them, particularly during the period in which the periodic report is being prepared; c. have evaluated the effectiveness of the issuer's disclosure controls and procedures as of a date within 90 days prior to the filing date of the report; and d. have presented in the report their conclusions about the effectiveness of the disclosure controls and procedures based on the required evaluation as of that date; 5. he and the other certifying officers have disclosed to the issuer's auditors and to the audit committee of the board of directors (or persons fulfilling the equivalent function): a. all significant deficiencies in the design or operation of internal controls (a pre-existing term relating to internal controls regarding financial reporting) which could adversely affect the issuer's ability to record, process, summarize and report financial data and have identified for the issuer's auditors any material weaknesses in internal controls; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer's internal controls; and 6. he and the other certifying officers have indicated in the report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. /s/ George Tsoukas ----------------------------- George Tsoukas Chairman of Board (Principal Executive Officer) FORM OF OFFICER'S CERTIFICATE PURSUANT TO SECTION 302 The undersigned Principal Financial Officer (Chief Operating Officer) of Millenia Hope Inc., hereby certifies that: 1. he has reviewed the report; 2. based on his knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report; 3. based on his knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in the report; 4. he and the other certifying officers: a. are responsible for establishing and maintaining "disclosure controls and procedures" (a newly-defined term reflecting the concept of controls and procedures related to disclosure embodied in Section 302(a)(4) of the Act) for the issuer; b. have designed such disclosure controls and procedures to ensure that material information is made known to them, particularly during the period in which the periodic report is being prepared; c. have evaluated the effectiveness of the issuer's disclosure controls and procedures as of a date within 90 days prior to the filing date of the report; and d. have presented in the report their conclusions about the effectiveness of the disclosure controls and procedures based on the required evaluation as of that date; 5. he and the other certifying officers have disclosed to the issuer's auditors and to the audit committee of the board of directors (or persons fulfilling the equivalent function): a. all significant deficiencies in the design or operation of internal controls (a pre-existing term relating to internal controls regarding financial reporting) which could adversely affect the issuer's ability to record, process, summarize and report financial data and have identified for the issuer's auditors any material weaknesses in internal controls; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the issuer's internal controls; and 6. he and the other certifying officers have indicated in the report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses. /s/ Leonard Stella ----------------------------- Leonard Stella Chief Operating Officer (Principal Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----